Prostate‐specific antigen (PSA) complexed to α1‐antichymotrypsin improves prostate cancer detection using total PSA in Japanese patients with total PSA levels of 2.0–4.0 ng/mL

To assess the utility of prostate‐specific antigen (PSA) complexed to α1‐antichymotrypsin (PSA‐ACT) in prostate cancer screening in Japanese men with a total PSA level of 2.0–4.0 ng/mL, as improving cancer detection in men with these total PSA levels is a challenge for clinical urologists.

[1]  A. Partin,et al.  Applying complexed prostate-specific antigen to clinical practice. , 2004, Urology.

[2]  H. Klocker,et al.  Proenzyme psa for the early detection of prostate cancer in the 2.5-4.0 ng/ml total psa range: preliminary analysis. , 2003, Urology.

[3]  T. Habuchi,et al.  Ratio of prostate specific antigen minor molecular forms-to-total prostate specific antigen is constant regardless of the pathological condition of the prostate. , 2003, The Journal of urology.

[4]  U. Stenman,et al.  Dual-label immunoassay for simultaneous measurement of prostate-specific antigen (PSA)-alpha1-antichymotrypsin complex together with free or total PSA. , 2003, Clinical chemistry.

[5]  H. Klocker,et al.  Screening with low PSA cutoff values results in low rates of positive surgical margins in radical prostatectomy specimens , 2002, The Prostate.

[6]  T. Stamey,et al.  Complexed prostate-specific antigen for early detection of prostate cancer in men with serum prostate-specific antigen levels of 2 to 4 nanograms per milliliter. , 2002, Urology.

[7]  D. Chan,et al.  Comparative analysis of complexed prostate specific antigen, free prostate specific antigen and their ratio in detecting prostate cancer. , 2002, The Journal of urology.

[8]  Y. Miyaji,et al.  Prostate specific antigen complexed to α‐1‐antichymotrypsin in patients with intermediate prostate specific antigen levels , 2002 .

[9]  Kazuto Ito,et al.  Effectiveness of mass screening for the prognosis of prostate cancer patients in Japanese communities , 2002, The Prostate.

[10]  Y. Miyaji,et al.  Prostate specific antigen complexed to alpha-1-antichymotrypsin in patients with intermediate prostate specific antigen levels. , 2002, Cancer.

[11]  H. Miyake,et al.  Value of prostate specific antigen α1‐antichymotrypsin complex for the detection of prostate cancer in patients with a PSA level of 4.1–10.0ng/mL: Comparison with PSA‐related parameters , 2001, International journal of urology : official journal of the Japanese Urological Association.

[12]  I. Ross,et al.  A prospective study to evaluate the role of complexed prostate specific antigen and free/total prostate specific antigen ratio for the diagnosis of prostate cancer. , 2001, The Journal of urology.

[13]  T. Niwa,et al.  Determination of serum prostate-specific antigen-alpha1-antichymotrypsin complex for diagnosis of prostate cancer in Japanese cases. , 2001, Scandinavian journal of urology and nephrology.

[14]  T. Tammela,et al.  Use of the complex between prostate specific antigen and alpha 1-protease inhibitor for screening prostate cancer. , 2000, The Journal of urology.

[15]  D. Chan,et al.  Complexed prostate specific antigen provides significant enhancement of specificity compared with total prostate specific antigen for detecting prostate cancer. , 2000, The Journal of urology.

[16]  S. Loening,et al.  Ratio of free or complexed prostate-specific antigen (PSA) to total PSA: which ratio improves differentiation between benign prostatic hyperplasia and prostate cancer? , 2000, Clinical chemistry.

[17]  S. Loening,et al.  Determination of alpha1-antichymotrypsin-PSA complex in serum does not improve the differentiation between benign prostatic hyperplasia and prostate cancer compared with total PSA and percent free PSA. , 1999, Urology.

[18]  J. Oesterling,et al.  Comparison of analysis of the different prostate-specific antigen forms in serum for detection of clinically localized prostate cancer. , 1996, Urology.

[19]  J. Moul,et al.  Age-specific reference ranges for serum prostate-specific antigen in black men. , 1996, The New England journal of medicine.

[20]  T. Stamey.  Second Stanford Conference on International Standardization of Prostate-Specific Antigen Immunoassays: September 1 and 2, 1994. , 1995, Urology.

[21]  C. Bangma,et al.  Age-specific reference ranges for prostate-specific antigen. , 1994, JAMA.

[22]  O. Nilsson,et al.  Prostate-specific antigen in serum occurs predominantly in complex with alpha 1-antichymotrypsin. , 1991, Clinical chemistry.

[23]  H. Lilja,et al.  Enzymatic activity of prostate-specific antigen and its reactions with extracellular serine proteinase inhibitors. , 1990, European journal of biochemistry.